Enliven Therapeutics, Inc. Financials

ELVN

All currency values in $ millions unless otherwise noted

Scroll

Showing 5 of 7 available years

Income Statement	DEC 2025	DEC 2024 ~1.3:1 split	DEC 2023	DEC 2022	DEC 2021 ~1.6:1 split
General & Administrative	$34	$24	$19	$8	$13
Research & Development	$86	$81	$65	$31	$38
Total Operating Expenses	$120	$105	$84	$39	$51
Operating Income	-$120	-$105	-$84	-$39	-$51
Other Non-Operating Income (Expense)	$16	$16	$12	$1	$0
EBT (Earnings Before Tax)	–	–	–	$2	-$51
Income Tax Expense	$0	$0	$0	$0	–
Net Income
Net Income	-$104	-$89	-$72	-$38	-$51
EPS (Basic)	-$1.83	-$1.89	-$2.01	-$12.05	-$2.37
EPS (Diluted)	-$1.83	-$1.89	-$2.01	-$12.05	-$2.37
Weighted Avg Shares (Basic)	56.7M	47.1M	35.5M	26.3M	21.7M
Weighted Avg Shares (Diluted)	56.7M	47.1M	35.5M	26.4M	21.7M
Shares Outstanding	56.7M	47.1M	35.5M	26.4M	21.7M

Enliven Therapeutics (ELVN) financials: revenue, profit and margins

Enliven Therapeutics (ELVN) generated about n/a in revenue and -$106 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Enliven Therapeutics profitable?+

Enliven Therapeutics reported about -$106 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

More on ELVN: Overview · Quality scorecard · DCF valuation · Dividend safety

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 28 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 6 Aug 2026. How this is calculated.

Fiscal year ends Dec.

Peers

Pharmaceutical Preparations · Pick stocks to compare with ELVN

CompareIntrinsic value

AKBAAkebia Therapeutics Inc.

$0.69-4.31%49

ACADAcadia Pharmaceuticals Inc.

$21.49+4.47%74

NAMSNewAmsterdam Pharma Co. N.V.

$20.93+5.18%10

EOLSEvolus Inc.

$7.47+1.36%30

MCRBSeres Therapeutics, Inc.

$2.13+8.42%0

ZVRAZevra Therapeutics, Inc.

$11.17+8.87%83

ARQTArcutis Biotherapeutics Inc.

$34.05+6.41%65

URGNUrogen Pharma Ltd.

$28.71-16.54%30

Held by ETFs

ELVN is in 45 US ETFs. The largest of them, with ELVN's weight in each:

Spot a number that looks wrong? Check it in ELVN's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ELVN

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.